Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA)

PURPOSE: In patients with platinum-sensitive relapsed (PSR) ovarian cancer, olaparib maintenance monotherapy significantly improves progression-free survival (PFS) versus placebo. However, evidence in the Asian population is lacking. This is the first study to evaluate olaparib efficacy and tolerabi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Qinglei, Zhu, Jianqing, Zhao, Weidong, Huang, Yi, An, Ruifang, Zheng, Hong, Qu, Pengpeng, Wang, Li, Zhou, Qi, Wang, Danbo, Lou, Ge, Wang, Jing, Wang, Ke, Low, John, Kong, Beihua, Rozita, Abdul Malik, Sen, Lim Chun, Yin, Rutie, Xie, Xing, Liu, Jihong, Sun, Wei, Su, Jingya, Zhang, Chunyi, Zang, Rongyu, Ma, Ding
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359747/
https://www.ncbi.nlm.nih.gov/pubmed/35131903
http://dx.doi.org/10.1158/1078-0432.CCR-21-3023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359747/
https://www.ncbi.nlm.nih.gov/pubmed/35131903
http://dx.doi.org/10.1158/1078-0432.CCR-21-3023

Ejemplares similares